666 results about "Nasal inflammation" patented technology

A pharmaceutical composition and formulations comprise preventative, prophylactic or therapeutic amounts of an oligo(s) anti-sense to a specific gene(s) or its corresponding mRNA(s), and a glucocorticoid and/or non-glucocorticoid steroid or a ubiquinone or their salts. The agents, composition and formulations are used for treatment of ailments associated with impaired respiration, bronchoconstriction, lung allergy(ies) or inflammation, and abnormal levels of adenosine, adenosine receptors, sensitivity to adenosine, lung surfactant and ubiquinone, such as pulmonary fibrosis, vasoconstriction, inflammation, allergies, allergic rhinitis, asthma, impeded respiration, lung pain, cystic fibrosis, bronchoconstriction, COPD, RDS, ARDS, cancer, and others. The present treatment is effectively administered by itself for conditions without known therapies, as a substitute for therapies exhibiting undesirable side effects, or in combination with other treatments, e.g. before, during and after other respiratory system therapies, radiation, chemotherapy, antibody therapy and surgery, among others. Each of the agents of this invention may be administered directly into the respiratory system so that they gain direct access to the lungs, or by other effective routes of administration. A kit comprises a delivery device, the agents and instructions for its use.

The present invention relates to herbal composition for the treatment of chronic respiratory disorders such as cold, cough, allergic asthma, seasonal allergic rhinitis, pharyngitis, laryngitis and the like and a process for preparing the same. The composition comprises extracts derived from Ayurvedic plants selected from the following group: The process for preparing the herbal composition of the present invention comprises procuring, cleaning, grading of specified herbal plants as per the standard specification, disintegrating and pulverizing separately to form the coarse powder, then macerating individual powders separately with aqueous solution of preservatives and then extracting, filtering, concentrating and spray drying to make dry extract powder or semisolid soft extract. Further dissolving each of the extracts separately in aqueous solution containing preservatives and then allowing to maturate after mixing. Then adding filtered extracts to the sugar syrup containing preservatives, glycerin and appropriate excipients to obtain a homogenous cough syrup. The herbal composition of the present invention is non alcoholic, non sedating and non-freezing in nature and the process of preparation as described above does not employ pharmaceutically unacceptable organic solvents.

The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (PI3K) inhibition, especially for PI3K-γ inhibition and can be used for the prophylaxis and treatment of diseases associated with PI3K and particularly with PI3K-γ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to PI3K activity in a human or animal subject.

The invention provides a method of treating rhinitis. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP) formulated for nasal administration. The invention also provides a pharmaceutical product comprising a DA-DKP containing composition.

The invention relates to a formula of a drug for treating rhinitis. The drug is a tea-bag type composite oral preparation and is utilized for treating acute and chronic rhinitis, nasosinusitis and prosopantritis. The drug for treating rhinitis comprises the following ingredients of angelica sinensis, radix astragali, rhizoma atractylodis macrocephalae, fangshui, keel, oyster, cassia twig, ligusticum wallichii, dahurian angelica root, ligusticum sinense oliver, cimicifuga foetida, flos magnoliae, monkshood, sparganium, curcuma rhizome, catnip, notopterygium root, levisticum, chrysanthemum, radix scrophulariae, radix bupleuri, cape jasmine fruit, the bulb of fritillary, xanthium, white peony root, little lotus, asarum herb, rhizoma anemarrhenae, silver flower, honey-fried licorice root, radix glehniae, poria cocos, tuber of dwarf lilyturf, root of large-flowered skullcap, gentian and mulberry leaf. Through many years of clinical application, the formula based on an ancestral "Bizutang" formula is obtained after modification. Through synergistic effects of the ingredients of the drug for treating rhinitis, the effects of tonifying qi and nourishing yin, promoting and tonifying the lung, activating blood circulation and dissipating blood stasis, clearing heat and draining dampness, reducing swelling and relieving pain, and restoring consciousness and unblocking orifices are obtained. The drug for treating rhinitis has the characteristics of obvious curative effects and convenient drug taking way.

The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The present invention relates to a nasal spray containing sodium pyruvate and a preparation method thereof, belonging to the field of medical technology, being characterized in that: the nasal spray containing sodium pyruvate comprises the following components: sodium pyruvate, pyruvic acid, an isoosmotic adjusting agent, a preservative and water. Because the sodium pyruvate is capable of alleviating nasal obstruction and inflammation caused by rhinitis, a medical fluid provided in the invention can be made into a nasal spray medical fluid which is capable of entering nasal cavities by adopting a portable spraying device. The nasal spray medical fluid is particularly suitable for cleaning and removing harmful pollutants in nasal passages, paranasal sinuses and mucosal cilia and is capable of being used in nursing after a nasal cavity operation, relieving rhinostegnosis and reducing respiratory tract irritation and risks of infection. By adding the pyruvic acid to form a buffer solution, tingling caused by using the flushing fluid to wash the cavities can be reduced, and inflammation is alleviated. Allergic symptoms can be prevented or gradually alleviated for the people of special professional who often use the product provided in the invention to wash and care nasal cavities.

A traditional Chinese medicine health-caring health maintaining pillow comprises an air-permeable pillowcase and filling. Traditional Chinese medicine composition is contained in the filling. The traditional Chinese medicine health-caring health maintaining pillow is characterized in that the traditional Chinese medicine composition comprises 24 natural Chinese herbal medicines including: radix bupleuri, ligusticum, galangal, asarum, radix angelicae, uncaria, rhizoma chuanxiong, sadix saposhnikoviae, honeysuckle flower, white silkworm, rhizoma acori graminei, fructus forsythia, gastrodia elata, cinnamon, rhizoma atractylodis, borneol, tuber fleeceflower stem, menthol, chrysanthemum, folium artemisiae argyi, mentha haplocalyx, cordate houttuynia, common bombax flower and semen sesami nigrum. Smell diffused by the traditional Chinese medicine health-caring health maintaining pillow can directly act on the respiratory system of a human body, particularly to the nasal mucosa, so that bacterium and virus cannot survive on the upper respiratory tract mucous membrane, influenza is prevented, patients suffering from chronic pharyngitis, rhinitis, migraine and bronchitis can be treated during resting, and sleeping quality can be improved.

Improved efficacy in treatment of rhinitis with botulinum toxin is obtained using liposomal encapsulated botulinum formulations for administration of the botulinum toxin. The liposomes are typically administered in a physiologically acceptable carrier such as saline or phosphate buffered saline by instillation into the nasal passages.

Apparatus and methods are disclosed for treating allergic rhinitis (seasonal and perennial hay fever), by application of flash lamp radiation. The nasal cavity can be illuminated in a safe and effective manner, with non-coherent light from a flash-lamp or other suitable source. This illumination can be accomplished in any suitable manner, including by use of a handheld device. Such handheld embodiments may contain a power source (battery or AC), control circuitry, light source (flash-lamp or diode laser), lens (focusing or non-focusing), light filter, and/or fiber-optic for delivering light to the nasal cavity. Embodiments include using any suitable light energy, such as visible light in the red wavelengths with a power output of 1 to 10 Joules per cm². The device can be pre-programmed to deliver a specified amount of light in a specified amount of time using multiple pulses (in the case of a flash lamp) or a continuous wave (in the case of a diode laser). In many useful embodiments, a rigid fiber-optic extends from the lens/light filter a length of 10 to 20 mm, although it can be any convenient and useful size and shape. Contact sensors can be arrayed on the device for various purposes, such as to restrict illumination to times when the fiber optic is inserted into the nasal cavity. This and/or other safety features can prevent the high-intensity light from being fired into open space, a person's eyes, and/or otherwise causing a potential vision or other hazard. Preferably, the device can be easily and comfortably inserted into a nostril. The fiber-optic can be angled (either in its own shape or by the user manipulating it to a convenient angle/position) so as to allow the user to easily grip the device and insert the fiber-optic without having to use a mirror or other aid. Light from the device can be emitted at a specified light frequency that causes a desired immunosuppressive response in the cellular system.

The present invention is directed to methods for treating rhinitis or sinusitis in a subject. In one embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a formulation comprising an only active ingredient of an effective amount of rhamnolipid. In another embodiment, the method comprises the steps of: identifying a subject in need thereof, and administering intranasally to the subject a first active ingredient of an effective amount of a rhamnolipid and a second active ingredient of an effective amount of a corticosteroid, an antihistamine, a leukotriene antagonist, cromylin, an antibiotic, a sphingolipid, or a decongestant.

The present invention provides cyclodextrin-free aqueous liquid formulations of rupatadine fumarate, useful for the treatment of allergic rhinitis and urticaria. Said formulations comprise rupatadine fumarate, one or more cosolvents and one or more pH regulating agents wherein the composition has a pH between 4 and 6.5.

A tansdermal delivery device for effectively treating seasonal allergic rhinitis and chronic idiopathic urticariain in humans is disclosed and methods thereof.

The invention discloses the drug of treating the nasal over-secretion and chronic obstructive emphysema, at the mean time, provides the drug compositions of treating the nasal over-secretion and chronic obstructive emphysema, which are aerosol, powder cloud agent, naristillae and spray. In the invention, the compositions, which are introduced quaternary ammonium group on the basis of penehyclidine hydrochloride, can't permeate membrane and enter into the circulatory system and central, so it can be used in treating the chronic obstructive emphysema. Besides, due to the low absorptivity in the mucous membrane position, the said new compositions are extended the resistance time at local, so it can be used in treating the chronic obstructive emphysema and coryza.